Moreover, CAR-T cells are genetically engineered to recognize and attack tumor-specific antigens (June et al., 2018), bypassing the need of MHC molecules presentation, and behaving as active drugs against tumors (Maus and June, 2016). The gene discussed is HLA-C; the disease is neoplasm.